Company intelligence
Merz Therapeutics
Better outcomes for more patients
About Merz Therapeutics
Merz Therapeutics GmbH is dedicated to delivering better outcomes for more patients. With science as its foundation and the patient experience as its focus, the company relentlessly pursues innovative treatments and partnerships to address unmet needs in movement disorders, neurodegenerative conditions, liver disease, and other health conditions that severely impact patients’ quality of life. Merz Therapeutics is headquartered in Frankfurt am Main, Germany, and is active in over 80 countries. Merz Therapeutics GmbH is part of the Merz Group, a privately held, family-owned company with a 117-year legacy. With passion and purpose, Merz Therapeutics continues to advance care in specialty neurology in ways that benefit both patients and society.
Verified activity
Signals from Merz Therapeutics
4 published signals
Presence & Recognition
Merz Therapeutics participated in the Global Strategy Forum in Vienna to align on strategy and priorities.
Reported by Luke Mircea-Willats
Presence & Recognition
Merz Therapeutics hosted its Global Strategic Forum in Vienna to discuss opportunities, challenges, and choices shaping the next fiscal year.
Reported by Merz Therapeutics
Research & Knowledge
Merz Therapeutics published a new S3 Connected Health for Pharma whitepaper by Claudia Cramer, VP Global Asset & Commercial Strategy, exploring how behavioral science helps pharma organizations identify global consistency and local adaptation.
Reported by Merz Therapeutics
Presence & Recognition
Merz Therapeutics held its Annual Sales Meeting (ASM) in Atlanta last month to celebrate achievements, learn from colleagues, and align on the new fiscal year ahead.
Reported by Merz Therapeutics